The decline in Lantern Pharma's stock price is directly related to the announcement of their Q4 financial results. Typically, a negative reaction in stock price following earnings reports can be attributed to the company not meeting market expectations, whether in terms of revenue, profits, or future guidance. Without specific details on the financial results, the assumption is that the results were unfavorable or below market expectations, leading to a decrease in investor confidence and a subsequent drop in stock price.